Theoretically, then, it is preferable for subjects with real hyperinsulinemia to quit or simplify insulin regimens and choose hypoglycemic agents that can improve insulin resistance, such as metformin, sodium-glucose cotransporter 2 (SGLT2) inhibitors, or glucagon-like peptide 1 receptor agonist (GLP-1RAs). The gene discussed is SLC5A2; the disease is hyperinsulinism.